Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Rising Today

By George Budwell - Mar 30, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company may be in line for more COVID-19 grant money.

What happened

Inovio Pharmaceuticals (INO 6.08%), a pre-revenue vaccine company, saw its shares rise by as much as 10% in pre-market trading Monday morning. The biotech's shares appear to be responding to the news that Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, through their Chan Zuckerberg Initiative, will donate $25 million to Bill Gates' accelerator program designed to speed up the development of various COVID-19 therapies. 

Inovio is currently developing a COVID-19 vaccine called INO-4800. The vaccine is slated to begin human trials next month. Top-line data from this highly anticipated trial should be available this fall, according to the company. While it will likely take years to get a full regulatory approval for any vaccine, Inovio plans on having 1 million doses of INO-4800 available for emergency purposes before the end of the year. 

Close up image of the novel coronavirus.

Image source: Getty Images.

So what

Inovio has so far received a $9 million grant from the Coalition for Epidemic Preparedness Innovations, as well as a $5 million grant from the Bill and Melinda Gates Foundation to advance INO-4800 into clinical trials. So there is definitely a fair amount of interest from these organizations in this experimental COVID-19 vaccine. As such, Inovio might be in line to receive a slice of the $25 million Chan Zuckerberg Initiative donation.  

Now what

Is Inovio's stock a top COVID-19 play? While Inovio does have a strong track record of hauling in grant money for its experimental vaccines in general, the real needle-moving event with this biotech stock will no doubt be the upcoming late-stage readout for the company's lead product candidate VGX-3100. In short, investors probably shouldn't buy this stock solely for its tie-in to the pandemic. INO-4800, after all, is only a small piece of the company's overall value proposition.   


Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.79 (6.08%) $0.16
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$180.89 (0.22%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.